Generic Name and Formulations:
Ocriplasmin 2.5mg/mL; per vial; soln for intravitreal inj after dilution; contains mannitol; preservative- and latex-free.
Indications for JETREA:
Treatment of symptomatic vitreomacular adhesion.
Give by intravitreal inj. 0.125mg (0.1mL of the diluted soln) once as a single dose to the affected eye.
For ophthalmic intravitreal inj only. Monitor for elevation in intraocular pressure immediately after inj. Monitor for decreased vision. Repeated administration in the same eye: not recommended. Treatment in the other eye is not recommended within 7 days of the initial inj. Pregnancy (Cat.C). Nursing mothers.
Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema; intraocular inflammation/infection/hemorrhage, increased intraocular pressure, yellowish vision.
Single-use vial (0.2mL)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|